参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6): 394-424.[2]Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.[3]Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group[J].World Health Organ Tech Rep Ser,1994(843):1-129.[4]Kanis JA,Johnell O,Oden A,et al.Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds[J].Osteoporos Int,2001,12(12):989-995.[5]Shapiro CL,Van Poznak C,Lacchetti C,et al.Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline[J].J Clin Oncol,2019, 37(31):2916-2946.[6]Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.[7]D’oronzo S,Coleman R,Brown J,et al.Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management[J].J Bone Oncol,2019(15):004-4.[8]孔令泉,吴凯南,果磊.乳腺癌伴随疾病学[M].北京:科学出版社,2019:74-94.[9]Nicolin V,Bortul R,Bareggi R,et al.Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway[J].Acta Histochem,2008,110(5):388-396.[10]Kyvernitakis I,Kostev K,Hadji P.The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer[J].Osteoporos Int,2018,29(11):2557-2564.[11]Kalder M,Hans D,Kyvernitakis I,et al.Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer[J].J Clin Densitom,2014,17(1):66-71.[12]Ramchand SK,Cheung YM,Grossmann M.Bone health in women with breast cancer[J].Climacteric,2019:1-7.[13]Ruhstaller T,Giobbie-Hurder A,Colleoni M,et al.Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial[J].J Clin Oncol,2019,37(2):105-114.[14]Hong AR,Kim JH,Lee KH,et al.Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer[J].Osteoporos Int,2017,28(4):1413-1422.[15]Tseng OL,Spinelli JJ,Gotay CC,et al.Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis[J].Ther Adv Musculoskelet Dis,2018, 10(4):71-90.[16]Axelsen CT,Jensen AB,Jakobsen EH,et al.Bone loss during neoadjuvant/adjuvant chemotherapy for early stage breast cancer: A retrospective cohort study[J].Mol Clin Oncol,2018,8(6):767-772.[17]Taxel P,Faircloth E,Idrees S,et al.Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer[J].J Endocr Soc,2018,2(7):574-588.[18]Bouvard B,Confavreux CB,Briot K,et al.French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies[J].Joint Bone Spine,2019,86(5):542-553.[19]Hadji P,Aapro MS,Body JJ,et al.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG[J].J Bone Oncol,2017(7):1-12.[20]中国乳腺癌内分泌治疗多学科管理骨安全共识专家组.绝经后早期乳腺癌芳香化酶抑制剂治疗相关的骨安全管理中国专家共识[J]中华肿瘤杂志,2015(7):554-558.[21]戴威,孔令泉,吴凯南.乳腺癌伴随疾病全方位管理之骨健康管理[J].中国临床新医学,2019(2):145-149.[22]Hillner BE,Ingle JN,Chlebowski RT,et al.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer[J].J Clin Oncol, 2003,21(21):4042-4057.[23]Henry D,Vadhan-Raj S,Hirsh V,et al.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors[J].Support Care Cancer,2014,22(3):679-687.
相似文献/References:
[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像
在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(07):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(07):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[4]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与
健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,31(07):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[5]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,31(07):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,31(07):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[7]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(07):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[8]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,31(07):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,31(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,31(07):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]张 乐,徐胜昔,郭翔取,等.Tyrer-Cuzick模型联合SNPs位点在江西地区乳腺癌诊断中应用研究[J].医学信息,2018,31(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Medical Information,2018,31(07):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]